Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T70888
|
|||||
| Target Name |
TNF receptor (TNFR)
|
|||||
| Synonyms |
TNFR
Click to Show/Hide
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 1 Target-related Diseases | + | ||||
| 1 | Crohn disease [ICD-11: DD70] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 1 Clinical Trial Drugs | + | ||||
| 1 | ETX201 | Drug Info | Phase 1 | Crohn disease | [2] | |
| Discontinued Drug(s) | [+] 2 Discontinued Drugs | + | ||||
| 1 | Lenercept | Drug Info | Discontinued in Phase 3 | Asthma | [3] | |
| 2 | BB-2275 | Drug Info | Terminated | Human immunodeficiency virus infection | [4] | |
| Mode of Action | [+] 2 Modes of Action | + | ||||
| Antagonist | [+] 1 Antagonist drugs | + | ||||
| 1 | ETX201 | Drug Info | [2] | |||
| Modulator | [+] 2 Modulator drugs | + | ||||
| 1 | Lenercept | Drug Info | [5] | |||
| 2 | BB-2275 | Drug Info | [6] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis. Skin Therapy Lett. 2003 Jan;8(1):1-4. | |||||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
| REF 3 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004745) | |||||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003251) | |||||
| REF 5 | Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controll... Crit Care Med. 2001 Mar;29(3):503-10. | |||||
| REF 6 | Paradoxical effects of a synthetic metalloproteinase inhibitor that blocks both p55 and p75 TNF receptor shedding and TNF alpha processing in RA sy... J Clin Invest. 1996 Jun 15;97(12):2833-41. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.